Paul Fields

机构：Adaptive Biotechnologies (United States) · ORCID：0000-0002-9608-6464

发表论文 116 篇 · 总被引 4547 次 · h-index 28

代表论文

• Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial (2023 · Nature Medicine · 被引 112)
• AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire (2021 · Science Translational Medicine · 被引 107)
• Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy (2023 · Cell stem cell · 被引 88)
• One‐Year Landmark Analysis of the Effect of Beta‐Blocker Dose on Survival After Acute Myocardial Infarction (2021 · Journal of the American Heart Association · 被引 25)
• Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies (2022 · Blood Cancer Discovery · 被引 24)
• Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer (2022 · Journal for ImmunoTherapy of Cancer · 被引 20)